This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain

Company Overview - Axsome Therapeutics is a clinical-stage biopharmaceutical company focused on therapeutics for central nervous system (CNS) disorders, with a strong late-stage pipeline addressing significant gaps in neuropsychiatric and neurological care [6] - The company reported a total revenue of $638.5 million for the trailing twelve months (TTM), reflecting a 66% increase from 2024 [4][12] - Axsome has a market capitalization of $8.1 billion and is currently trading at $158.40 per share, which is a 27% increase over the past year, outperforming the S&P 500's 19% gain [4][7] Product Pipeline - Axsome's pipeline includes AXS-05 for major depressive disorder and Alzheimer's disease agitation, AXS-07 for migraine, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia [8] - The company has initiated a Phase 3 trial for solriamfetol targeting major depressive disorder with excessive daytime sleepiness, which presents an additional label expansion opportunity [11] Investment Position - Superstring Capital Management disclosed a new position in Axsome Therapeutics, acquiring 37,433 shares valued at $6.84 million, representing nearly 4% of its 13F assets under management [2][7] - This investment reflects a strategic shift towards a company that is already generating revenue, contrasting with earlier-stage biotech investments that are more reliant on clinical trial outcomes [9][10]